Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF 9.86
(2.49%)
CHF 9.86
(2.49%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 49.68 Million CHF | -53.74% |
| 2022 | 107.41 Million CHF | 19.63% |
| 2021 | 89.78 Million CHF | -5.53% |
| 2020 | 95.04 Million CHF | 1.32% |
| 2019 | 93.8 Million CHF | 13.75% |
| 2018 | 82.46 Million CHF | 6.37% |
| 2017 | 77.52 Million CHF | 371.53% |
| 2016 | 16.44 Million CHF | 50.77% |
| 2015 | 10.9 Million CHF | 91.08% |
| 2014 | 5.7 Million CHF | 117.0% |
| 2013 | 2.63 Million CHF | -59.88% |
| 2012 | 6.55 Million CHF | -27.57% |
| 2011 | 9.05 Million CHF | -0.97% |
| 2010 | 9.13 Million CHF | -18.32% |
| 2009 | 11.18 Million CHF | 32.05% |
| 2008 | 8.47 Million CHF | -2.17% |
| 2007 | 8.66 Million CHF | -16.29% |
| 2006 | 10.34 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 60.18 Million CHF | 21.14% |
| 2024 Q2 | 60.18 Million CHF | 0.0% |
| 2023 Q4 | 49.68 Million CHF | 0.0% |
| 2023 FY | 49.68 Million CHF | -53.74% |
| 2023 Q1 | 105.83 Million CHF | -1.47% |
| 2023 Q3 | 49.68 Million CHF | -53.05% |
| 2023 Q2 | 105.83 Million CHF | 0.0% |
| 2022 Q3 | 107.41 Million CHF | 14.72% |
| 2022 FY | 107.41 Million CHF | 19.63% |
| 2022 Q4 | 107.41 Million CHF | 0.0% |
| 2022 Q1 | 93.62 Million CHF | 4.27% |
| 2022 Q2 | 93.62 Million CHF | 0.0% |
| 2021 Q2 | 71.86 Million CHF | 0.0% |
| 2021 FY | 89.78 Million CHF | -5.53% |
| 2021 Q4 | 89.78 Million CHF | 0.0% |
| 2021 Q3 | 89.78 Million CHF | 24.94% |
| 2021 Q1 | 71.86 Million CHF | -24.39% |
| 2020 Q2 | 99.86 Million CHF | 0.0% |
| 2020 Q1 | 99.86 Million CHF | 6.46% |
| 2020 FY | 95.04 Million CHF | 1.32% |
| 2020 Q4 | 95.04 Million CHF | 0.0% |
| 2020 Q3 | 95.04 Million CHF | -4.83% |
| 2019 Q2 | 96.83 Million CHF | 0.0% |
| 2019 Q3 | 93.8 Million CHF | -3.13% |
| 2019 FY | 93.8 Million CHF | 13.75% |
| 2019 Q4 | 93.8 Million CHF | 0.0% |
| 2019 Q1 | 96.83 Million CHF | 17.43% |
| 2018 Q2 | 76.97 Million CHF | 0.0% |
| 2018 Q1 | 76.97 Million CHF | -0.71% |
| 2018 Q4 | 82.46 Million CHF | 11.49% |
| 2018 Q3 | 73.96 Million CHF | -3.91% |
| 2018 FY | 82.46 Million CHF | 6.37% |
| 2017 Q2 | 74.95 Million CHF | 0.0% |
| 2017 Q1 | 74.95 Million CHF | 355.9% |
| 2017 Q4 | 77.52 Million CHF | 0.0% |
| 2017 FY | 77.52 Million CHF | 371.53% |
| 2016 Q1 | 10.08 Million CHF | -7.48% |
| 2016 Q3 | 10.25 Million CHF | -34.62% |
| 2016 Q4 | 16.44 Million CHF | 60.27% |
| 2016 Q2 | 15.69 Million CHF | 55.52% |
| 2016 FY | 16.44 Million CHF | 50.77% |
| 2015 FY | 10.9 Million CHF | 91.08% |
| 2015 Q1 | 4.47 Million CHF | -21.57% |
| 2015 Q2 | 7.17 Million CHF | 60.23% |
| 2015 Q3 | 6.94 Million CHF | -3.12% |
| 2015 Q4 | 10.9 Million CHF | 56.95% |
| 2014 Q3 | 3.02 Million CHF | -3.48% |
| 2014 Q1 | 1.77 Million CHF | -32.66% |
| 2014 FY | 5.7 Million CHF | 117.0% |
| 2014 Q4 | 5.7 Million CHF | 88.54% |
| 2014 Q2 | 3.13 Million CHF | 77.08% |
| 2013 Q4 | 2.63 Million CHF | 61.05% |
| 2013 Q3 | 1.63 Million CHF | -53.24% |
| 2013 Q2 | 3.49 Million CHF | 62.12% |
| 2013 Q1 | 2.15 Million CHF | -67.14% |
| 2013 FY | 2.63 Million CHF | -59.88% |
| 2012 Q2 | 7.67 Million CHF | 0.0% |
| 2012 Q3 | 6.92 Million CHF | -9.78% |
| 2012 Q4 | 6.55 Million CHF | -5.27% |
| 2012 FY | 6.55 Million CHF | -27.57% |
| 2011 Q4 | 9.05 Million CHF | 0.0% |
| 2011 FY | 9.05 Million CHF | -0.97% |
| 2011 Q2 | 10.84 Million CHF | 0.0% |
| 2010 FY | 9.13 Million CHF | -18.32% |
| 2010 Q2 | 10.26 Million CHF | 0.0% |
| 2010 Q4 | 9.13 Million CHF | 0.0% |
| 2009 FY | 11.18 Million CHF | 32.05% |
| 2009 Q4 | 11.18 Million CHF | 0.0% |
| 2008 FY | 8.47 Million CHF | -2.17% |
| 2007 FY | 8.66 Million CHF | -16.29% |
| 2006 FY | 10.34 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Addex Therapeutics Ltd | 3.49 Million CHF | -1321.054% |
| BB Biotech AG | 304.9 Million CHF | 83.704% |
| Basilea Pharmaceutica AG | 183.29 Million CHF | 72.892% |
| Evolva Holding SA | 4.27 Million CHF | -1062.083% |
| Idorsia Ltd | 1.46 Billion CHF | 96.617% |
| Kuros Biosciences AG | 19.19 Million CHF | -158.862% |
| Molecular Partners AG | 21.92 Million CHF | -126.639% |
| Relief Therapeutics Holding AG | 24.16 Million CHF | -105.637% |